Methylation sequencing features
a lower limit of detection (LoD)
and improves ability to exclude clonal hematopoiesis noise.¹
Methylation-based detection identifies and quantifies
tumor signals in early- and late-stage cancers with
as low as 0.001% circulating tumor fraction (TF).¹
Methylation-based tumor fraction has superior sensitivity, enabling identification of tumor signal in 15%-50% more cancer patients.¹
QUANTIFY CANCER
Methylation
sequencing dramatically improves sensitivity
in cancer monitoring vs genomic signals alone.¹
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma